BioSpace News Archive

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the fourth quarter and full year ended December 31, 2020.

ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference.

Topline Results from a Phase 2a Trial of MET409 in Combination with Empagliflozin in Patients with NASH and Type 2 Diabetes Expected in the First Half of 2022

SQZ Biotech, a cell therapy company developing novel treatments for multiple therapeutic areas, reported full year 2020 financial results and recent business highlights.

After launching highly successful managed testing programs for colleges, GENETWORx leverages testing program expertise and capacity to help K-12 schools

Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Wednesday, March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the three months and full year ended December 31, 2020,

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the results of the 12-month analysis from the company’s post-market BRAVO study evaluating the clinical performance of OviTex Reinforced Tissue Matrix for the treatment of ventral hernias.

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA On track to submit NDA for AT-007 in Galactosemia no later than Q3 2021; Commercial preparations underway ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy on track to complete enrollment in mid-2021

KISQALI ® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners and the broadest spectrum of patients in two Phase III trials in advanced breast cancer .

Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of $11.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on March 18, 2021 under the symbol “GANX.”